百济神州抗癌药物新增适应症入医保

财中社
29 Nov 2024

  百济神州(688235/06160/BGNE)发布自愿披露公告,宣布其自主研发的抗PD-1抗体药物百泽安®和BTK抑制剂百悦泽®分别新增三项和一项适应症被纳入国家医保目录。此外,合作引进的产品百拓维®也新增一项适应症被纳入,而凯洛斯®成功续约。国家医保目录将于2025年1月1日起正式实施。

  此次新增适应症的纳入,将有助于提高相关产品在患者中的可负担性和可及性,进而促进市场推广和销售,对公司的长期经营发展产生积极影响。百泽安®的新增适应症包括多种癌症治疗,而百悦泽®则新增了复发或难治性滤泡性淋巴瘤的适应症。百拓维®和凯洛斯®的新增适应症及续约也进一步增强了公司的产品线。

  2024年前三季度,百济神州-U实现收入191.36亿元,归母净利润-36.87亿元。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10